m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03377)
Name
Brolucizumab
Status
Approved
TTD Drug ID
D5DO9L
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Vascular endothelial growth factor A (VEGFA)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Brolucizumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Brolucizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Brolucizumab. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Brolucizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Brolucizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Brolucizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). [1], [2]
References
Ref 1 m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death Dis. 2022 May 21;13(5):483. doi: 10.1038/s41419-022-04950-2.
Ref 2 Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration